Isabel DeLaura

Isabel DeLaura

Auto-generated profile, based on publicly available information

Isabel DeLaura

Duke Transplant Center, Department of Surgery Duke University School of Medicine Durham North Carolina USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
IAImran J. Anwar
Imran J. Anwar
DBDora M. Berman
Dora M. Berman
IDIsabel DeLaura
Isabel DeLaura
QGQimeng Gao
Qimeng Gao
MWMelissa A. Willman
Melissa A. Willman
NKNorma S. Kenyon
Norma S. Kenyon
Prior studies of anti-CD40 ligand (CD40L)–based immunosuppression demonstrated effective prevention of islet and kidney allograft rejection in nonhuman primate models; however, clinical development was halted because of thromboembolic complications. An anti-CD40L-specific monoclonal antibody, AT-1501 (Tegoprubart), was engineered to minimize risk of thromboembolic complications by reducing binding to Fcγ receptors expressed on platelets while preserving binding to CD40L. AT-1501 was tested in both a cynomolgus macaque model of intrahepatic islet allotransplantation and a rhesus macaque model of kidney allotransplantation. AT-1501 monotherapy led to long-term graft survival in both islet and kidney transplant models, confirming its immunosuppressive potential. Furthermore, AT-1501–based regimens after islet transplant resulted in higher C-peptide, greater appetite leading to weight gain, and reduced occurrence of cytomegalovirus reactivation compared with conventional immunosuppression. These data support AT-1501 as a safe and effective agent to promote both islet and kidney allograft survival and function in nonhuman primate models, warranting further testing in clinical trials.

25 December 2024 in Liver Transplantation
Verified
Journal Article
Open access
QGQimeng Gao
Qimeng Gao
IAIsaac S. Alderete
Isaac S. Alderete
NANihal Aykun
Nihal Aykun
KSKannan P. Samy
Kannan P. Samy
CNChristopher L. Nauser
Christopher L. Nauser
ABAndrew S. Barbas
Andrew S. Barbas
Normothermic machine perfusion (NMP) facilitates the utilization of marginal liver allografts. It remains unknown whether clinical benefits offset additional costs in the real-world setting. We performed a comparison of outcomes and hospitalization costs for donor livers preserved by NMP versus static cold storage at a high-volume center. Adult patients receiving deceased donor liver transplants preserved by either NMP (TransMedics Organ Care System) or static cold storage between January 1, 2021, and December 31, 2023, were included. Donor and recipient characteristics, operative parameters, post-transplant outcomes, and hospitalization costs were compared. A total of 144 NMP and 149 static cold storage cases were included. A higher proportion of NMP cases were donation after circulatory death (38.2% vs. 4.7%, p<0.001). Despite a significantly higher Liver Donor Risk Index (2.1 vs. 1.7, p<0.001) and longer preservation time (877 vs. 355 min, p<0.001), recipients of NMP experienced lower rates of reperfusion syndrome (4.3% vs. 32.9%, p<0.001), less blood loss (1.5 vs. 3.0 L, p<0.001), and required less blood product transfusion. This resulted in shorter operative time for NMP cases (357 vs. 438 min, p<0.001) and significant reductions in both intensive care unit (3 vs. 5 d, p=0.005) and hospital length of stay (11 vs. 13 d, p=0.03). NMP facilitated the transition of cases to daytime hours (88.9% vs. 46.3%, p<0.001). Despite the clinical and logistical benefits observed, index hospitalization costs were significantly higher in the NMP cohort ($256,810 vs. $209,144, p<0.001), driven largely by higher organ acquisition costs ($135,930 vs. $50,940, p<0.001). In conclusion, utilization of NMP comes with an attendant increase in cost but provides substantial clinical benefit. Transplant programs must weigh these considerations in their practice environments before initiating an NMP program.

19 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
IDIsabel F. Delaura
Isabel F. Delaura
QGQimeng Gao
Qimeng Gao
IAImran J. Anwar
Imran J. Anwar
NANader Abraham
Nader Abraham
RKRiley Kahan
Riley Kahan
ABAndrew S. Barbas
Andrew S. Barbas
Organ shortages and an expanding waitlist have led to increased utilization of marginal organs. All donor organs are subject to varying degrees of IRI during the transplant process. Extended criteria organs, including those from older donors and organs donated after circulatory death are especially vulnerable to ischemia-reperfusion injury (IRI). Involvement of the complement cascade in mediating IRI has been studied extensively. Complement plays a vital role in the propagation of IRI and subsequent recruitment of the adaptive immune elements. Complement inhibition at various points of the pathway has been shown to mitigate IRI and minimize future immune-mediated injury in preclinical models. The recent introduction ofex vivomachine perfusion platforms provides an ideal window for therapeutic interventions. Here we review the role of complement in IRI by organ system and highlight potential therapeutic targets for intervention duringex vivomachine preservation of donor organs.

7 March 2023 in Xenotransplantation
Verified
Journal Article
Closed access
IDIsabel DeLaura
Isabel DeLaura
IAImran J. Anwar
Imran J. Anwar
JLJoseph M Ladowski
Joseph M Ladowski
APAlejandra Patino
Alejandra Patino
SCSarah Cantrell
Sarah Cantrell
SSScott Sanoff
Scott Sanoff

12 June 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMiriam Manook
Miriam Manook
DODanae Olaso
Danae Olaso
IAImran Anwar
Imran Anwar
IDIsabel DeLaura
Isabel DeLaura
JYJanghoon Yoon
Janghoon Yoon
JKJean Kwun
Jean Kwun
Genetic modification of porcine donors, combined with optimized immunosuppression, has been shown to improve outcomes of experimental xenotransplant. However, little is known about outcomes in sensitized recipients, a population that could potentially benefit the most from the clinical implementation of xenotransplantation. Here, five highly allosensitized rhesus macaques received a porcine kidney from GGTA1 (α1,3-galactosyltransferase) knockout pigs expressing the human CD55 transgene (1KO.1TG) and were maintained on an anti-CD154 monoclonal antibody (mAb)–based immunosuppressive regimen. These recipients developed de novo xenoreactive antibodies and experienced xenograft rejection with evidence of thrombotic microangiopathy and antibody-mediated rejection (AMR). In comparison, three highly allosensitized rhesus macaques receiving a kidney from GGTA1 , CMAH (cytidine monophospho- N -acetylneuraminic acid hydroxylase), and b4GNT2 / b4GALNT2 (β-1,4- N -acetyl-galactosaminyltransferase 2) knockout pigs expressing seven human transgenes including human CD46 , CD55 , CD47 , THBD (thrombomodulin), PROCR (protein C receptor), TNFAIP3 (tumor necrosis factor–α–induced protein 3), and HMOX1 (heme oxygenase 1) (3KO.7TG) experienced significantly prolonged graft survival and reduced AMR, associated with dampened post-transplant humoral responses, early monocyte and neutrophil activation, and T cell repopulation. After withdrawal of all immunosuppression, recipients who received kidneys from 3KO.7TG pigs rejected the xenografts via AMR. These data suggest that allosensitized recipients may be suitable candidates for xenografts from genetically modified porcine donors and could benefit from an optimized immunosuppression regimen designed to target the post-transplant humoral response, thereby avoiding AMR.

21 October 2023 in Xenotransplantation
Verified
Journal Article
Closed access
IDIsabel DeLaura
Isabel DeLaura
JZJoanna Zikos
Joanna Zikos
IAImran J. Anwar
Imran J. Anwar
JYJanghoon Yoon
Janghoon Yoon
JLJoseph Ladowski
Joseph Ladowski
JKJean Kwun
Jean Kwun